ATXS
Astria Therapeutics, Inc. [ATXS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ATXS Stock Summary
Top 10 Correlated ETFs
ATXS
Top 10 Correlated Stocks
ATXS
In the News
ATXS Financial details
Company Rating
Neutral
Market Cap
593.5M
Income
-70.59M
Revenue
0
Book val./share
6.66
Cash/share
6.75
Dividend
-
Dividend %
-
Employees
59
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-4.32
Forward P/E
-
PEG
1.27
P/S
-
P/B
1.2
P/C
1.56
P/FCF
-5.88
Quick Ratio
20.12
Current Ratio
20.41
Debt / Equity
0
LT Debt / Equity
-
-
-
EPS (TTM)
-2.26
EPS next Y
-
EPS next Q
-
EPS this Y
-29.45%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
36.51%
-
-
-
-
SMA20
-28.16%
SMA50
-16.7%
SMA100
144.35%
Inst Own
68.71%
Inst Trans
0.78%
ROA
-27%
ROE
-25%
ROC
-0.34%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.26-16.9
52W High
-34.13%
52W Low
+163.5%
RSI
31.93
Rel Volume
0.31
Avg Volume
1.04M
Volume
319.18K
Perf Week
-8.27%
Perf Month
-28.3%
Perf Quarter
124.73%
Perf Half Y
83.62%
-
-
-
-
Beta
0.707
-
-
Volatility
0.27%, 1.89%
Prev Close
-0.09%
Price
10.54
Change
-5.72%
ATXS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -14.06 | -12.12 | -3.38 | -3.43 | -2.42 | |
| Operating cash flow per share | -14.23 | -10.62 | -3.38 | -2.98 | -2.27 | |
| Free cash flow per share | -14.24 | -10.63 | -3.38 | -2.98 | -2.27 | |
| Cash per share | 19.42 | 14.69 | 14.06 | 15.49 | 8.19 | |
| Book value per share | 19.14 | 13.3 | 13.7 | 15.13 | 8.07 | |
| Tangible book value per share | 19.14 | 13.3 | 13.7 | 15.13 | 8.07 | |
| Share holders equity per share | 19.14 | 13.3 | 13.7 | 15.13 | 8.07 | |
| Interest debt per share | 1.21 | 0.34 | 0.04 | -0.05 | 0.01 | |
| Market cap | 66.19M | 39.27M | 48.11M | 217.7M | 231.35M | |
| Enterprise value | 58.54M | 15.39M | -38.04M | 198.12M | 55.98M | |
| P/E ratio | -2.52 | -1.06 | -1.59 | -4.34 | -3.17 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -2.49 | -1.21 | -1.6 | -5 | -3.38 | |
| PFCF ratio | -2.49 | -1.21 | -1.59 | -4.99 | -3.38 | |
| P/B Ratio | 1.85 | 0.97 | 0.39 | 0.98 | 0.95 | |
| PTB ratio | 1.85 | 0.97 | 0.39 | 0.98 | 0.95 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -2.23 | -0.41 | -0.28 | -3.7 | -0.83 | |
| EV to operating cash flow | -2.2 | -0.47 | 1.26 | -4.55 | -0.82 | |
| EV to free cash flow | -2.2 | -0.47 | 1.26 | -4.54 | -0.82 | |
| Earnings yield | -0.4 | -0.94 | -0.63 | -0.23 | -0.32 | |
| Free cash flow yield | -0.4 | -0.83 | -0.63 | -0.2 | -0.3 | |
| Debt to equity | 0.06 | 0.03 | 0 | 0 | 0 | |
| Debt to assets | 0.05 | 0.02 | 0 | 0 | 0 | |
| Net debt to EBITDA | 0.29 | 0.64 | -0.64 | 0.37 | 2.59 | |
| Current ratio | 7.74 | 7.25 | 24.42 | 389.07 | 21.73 | |
| Interest coverage | 0 | 0 | 0 | 32.06 | 0 | |
| Income quality | 1.01 | 0.87 | 0.15 | 0.84 | 0.94 | |
| Dividend Yield | 0 | 0 | 0.51 | 0 | 0 | |
| Payout ratio | 0 | 0 | -0.81 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.46 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 77.81 | 60.21 | 32.29 | 34.18 | 20.96 | |
| ROIC | -0.67 | -0.87 | -0.25 | -0.23 | -0.28 | |
| Return on tangible assets | -0.63 | -0.78 | -0.24 | -0.22 | -0.29 | |
| Graham Net | 16.17 | 12.47 | 13.48 | 14.84 | 7.81 | |
| Working capital | 33.93M | 39.94M | 121.87M | 225.86M | 239.39M | |
| Tangible asset value | 35.72M | 40.67M | 122.31M | 221.22M | 243.12M | |
| Net current asset value | 32.9M | 39.54M | 121.87M | 217.02M | 239.39M | |
| Invested capital | 0.06 | 0.03 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.3M | 1.37M | 1.55M | 1.17M | 1.15M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 16.8K | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.02 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.73 | -0.91 | -0.25 | -0.23 | -0.3 | |
| Capex per share | -0.01 | -0.01 | 0 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.66 | -0.32 | -0.45 | -0.63 | -0.86 | |
| Operating cash flow per share | -0.58 | -0.47 | -0.38 | -0.51 | -0.83 | |
| Free cash flow per share | -0.58 | -0.47 | -0.38 | -0.51 | -0.83 | |
| Cash per share | 12.29 | 7.63 | 7.24 | 6.73 | 6.75 | |
| Book value per share | 12.01 | 7.56 | 7.15 | 6.58 | 6.66 | |
| Tangible book value per share | 12.01 | 7.56 | 7.15 | 6.58 | 6.66 | |
| Share holders equity per share | 12.01 | 7.56 | 7.15 | 6.58 | 6.66 | |
| Interest debt per share | 0 | -0.05 | 0.02 | 0.02 | 0.01 | |
| Market cap | 274.23M | 371.66M | 233.43M | 209.18M | 280.5M | |
| Enterprise value | 254.65M | 170.15M | 100.11M | 89.86M | 105.13M | |
| P/E ratio | -5.6 | -10.46 | -4.64 | -2.95 | -2.23 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -25.72 | -28.04 | -21.82 | -14.67 | -9.28 | |
| PFCF ratio | -25.64 | -28.03 | -21.82 | -14.67 | -9.27 | |
| P/B Ratio | 1.24 | 1.76 | 1.16 | 1.13 | 1.15 | |
| PTB ratio | 1.24 | 1.76 | 1.16 | 1.13 | 1.15 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -17.82 | -12.61 | -6.63 | -4.44 | -5.53 | |
| EV to operating cash flow | -23.88 | -12.84 | -9.36 | -6.3 | -3.48 | |
| EV to free cash flow | -23.81 | -12.83 | -9.36 | -6.3 | -3.48 | |
| Earnings yield | -0.04 | -0.02 | -0.05 | -0.08 | -0.11 | |
| Free cash flow yield | -0.04 | -0.04 | -0.05 | -0.07 | -0.11 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 1.37 | 14.93 | 8.83 | 5.9 | 9.23 | |
| Current ratio | 389.07 | 32.29 | 30.98 | 20.41 | 21.73 | |
| Interest coverage | 13.91 | 5.85 | 0 | 0 | 0 | |
| Income quality | 0.8 | 1.18 | 0.85 | 0.8 | 0.96 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 13.4 | 7.36 | 8.49 | 9.67 | 11.35 | |
| ROIC | -0.06 | -0.05 | -0.07 | -0.11 | -0.08 | |
| Return on tangible assets | -0.05 | -0.04 | -0.06 | -0.09 | -0.12 | |
| Graham Net | 11.78 | 7.39 | 7.01 | 6.4 | 6.44 | |
| Working capital | 225.86M | 208.77M | 197.82M | 182.08M | 239.39M | |
| Tangible asset value | 221.22M | 211.36M | 200.4M | 184.48M | 243.12M | |
| Net current asset value | 217.02M | 208.57M | 197.76M | 182.08M | 239.39M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 789K | 859K | 879.5K | 983.5K | 1.33M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.06 | -0.04 | -0.06 | -0.1 | -0.13 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ATXS Frequently Asked Questions
What is Astria Therapeutics, Inc. stock symbol ?
Astria Therapeutics, Inc. is a US stock , located in Boston of Ma and trading under the symbol ATXS
What is Astria Therapeutics, Inc. stock quote today ?
Astria Therapeutics, Inc. stock price is $10.54 today.
Is Astria Therapeutics, Inc. stock public?
Yes, Astria Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.04M
- Market Capitalization 593.5M
- Employee 59
- CEO Ms. Jill C. Milne Ph.D.
- Headquarters Boston,MA,US
- IPO Date 2015-06-25
-
Website
https://www.astriatx.com 
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
